Novo Nordisk A/S (NVO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Novo Nordisk A/S, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Novo Nordisk A/S (NVO) has returned -25.12% so far this year and -44.52% over the past 12 months. Over the last ten years, NVO has returned 5.13% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jan 4, 1982, NVO's average daily return is +0.07%, while the average monthly return is +1.40%. At this rate, your investment would double in approximately 4.2 years.

Historically, 59% of months were positive and 41% were negative. The best month was Jan 1985 with a return of +29.0%, while the worst month was Feb 2026 at -37.0%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 6 months.

On a daily basis, NVO closed higher 49% of trading days. The best single day was Oct 21, 1987 with a return of +17.9%, while the worst single day was Oct 19, 1987 at -26.1%.

Novo Nordisk A/S has an annualized alpha of 11.77%, beta of 0.60, and R² of 0.13 versus S&P 500 Index. Calculated based on daily prices since January 05, 1982.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (83.42%) than losses (58.15%) — typical of diversified or defensive assets.
• Beta of 0.60 may look defensive, but with R² of 0.13 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.13 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NVO ranks 10 for risk / return — in the bottom 10% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and compare them to a chosen benchmark (S&P 500 Index).

Novo Nordisk A/S provided a 5.06% dividend yield over the last twelve months, with an annual payout of $1.86 per share. The company has been increasing its dividends for 7 consecutive years.

The table displays the monthly dividend distributions for Novo Nordisk A/S. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Novo Nordisk A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Novo Nordisk A/S was 74.70%, occurring on Mar 27, 2026. The portfolio has not yet recovered.

The current Novo Nordisk A/S drawdown is 73.25%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Novo Nordisk A/S over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Novo Nordisk A/S is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.